Comparison of efficacy and safety of denosumab versus zoledronic acid for treating skeletal-related events caused by bone metastasis in patients with maligmant solid tumors and multiple myeloma: A Meta-analysis of randomized controlled trials
Guang-lei QIAO,Shui-er ZHENG,Wei-xiang QI,Da-liu MIN,Zan SHEN,Yang YAO
DOI: https://doi.org/10.3781/j.issn.1000-7431.2013.01.008
2013-01-01
Tumor
Abstract:Objective: To assess the efficacy and safety of denosumab compared with zoledronic acid in treatment of SREs (skeletal-related events) caused by bone metastasis of malignant solid tumors and multiple myeloma. Methods: A computer-based online search was performed by using Cochrane Library, PubMed, EMBase, CNKI (China National Knowledge Infrastructure), Wanfang database and VIP database. Studies reporting RCT (randomized controlled trial) in accordance with the inclusion and exclusion criteria were included. Quality of the studies was assessed with Jadad score. The results were independently extracted by two reviewers. The data were analyzed using RevMan 5.0 software. Results: A total of three RCTs including 5 723 patients were involved in this Meta-analysis. Analysis of RCTs showed that denosumab was superior to zoledronic acid in delaying the time to the onset of first SRE during study period by 17% [HR (hazard ratio) = 0.83, 95% CI (confidence interval): 0.76-0.90; P < 0.000 1]. Mean time of delay to the onset of first SRE was 4.3 months. Denosumab was also superior to zoledronic acid in delaying the time to first and subsequent SREs during study period by 17% [RR (rate ratio) = 0.83, 95% CI: 0.76-0.90; P < 0.000 01]. There were no significant differences in OS (overall survival) (HR = 0.98, 95% CI : 0.91-1.06; P = 0.64), PFS (progressionfree survival) (HR = 1.01, 95% CI: 0.95-1.08; P = 0.72) and incidence rates of AEs (adverse events) [OR (odds ratio) = 0.86, 95% CI: 0.65-1.15; P = 0.31], SAEs (serious AEs) (OR = 0.96, 95% CI: 0.87-1.07; P = 0.49), nausea (OR = 0.97, 95% CI: 0.86-1.08; P = 0.55), fatigue (OR = 1.01, 95% CI: 0.83-1.22; P = 0.94), back pain (OR = 0.95, 95% CI: 0.84-1.07; P = 0.36) and ONJ (osteonecrosis of the jaw) (OR = 1.42, 95% CI: 0.95-2.13; P = 0.09) between denosumab group and zoledronic acid group. But denosumab group had lower incidence rates of anemia (OR = 0.86, 95% CI: 0.76-0.96; P = 0.009), renal toxicity-associated AEs (OR = 0.73, 95% CI: 0.55-0.96; P = 0.02) and acute-phase reactions (OR = 0.37, 95% CI: 0.32-0.43; P < 0.000 01) and higher incidence rate of hypocalcemia (OR = 2.05, 95% CI: 1.66-2.53; P < 0.000 01) as compared with zoledronic acid group. Conclusion: Denosumab was superior to zoledronic acid in delaying SREs caused by bone metastasis of malignant solid tumors and multiple myeloma. For safety, as compared with zoledronic acid, the incidence rates of anemia, renal toxicity-associated AEs and acute-phase reactions caused by denosumab are remarkably lower but the incidence rate of hypocalcemia is much higher. Copyright © 2013 by TUMOR.